基线18F-FDG PET／CT最大标准摄取值与B细胞非霍奇金淋巴瘤临床疗效及预后的关系

doi:10.3969/j.issn.1006-7795.2021.05.021

摘要/Abstract

摘要： 目的评估18氟-氟代脱氧葡萄糖-正电子发射计算机断层显像/电子计算机断层扫描(¹⁸F-flurodeoxyglucose positron emission tomography/computed tomography,¹⁸F-FDG PET/CT)的最大标准化摄取值(maximum standard uptake value, SUV_max)与B细胞非霍奇金淋巴瘤的疗效及预后的关系。方法分析2016年8月至2019年9月于首都医科大学附属北京世纪坛医院收治的初治弥漫大B细胞淋巴瘤及滤泡性淋巴瘤患者共47例,评估基线SUV_max与各临床病理因素、实验室化验指标之间的相关性,用受试者工作特征(receiver operating characteristic, ROC)曲线分析法确定基线SUV_max对疾病进展的最佳临界点,分析其对治疗疗效及生存的预后、预测价值。结果 ①乳酸脱氢酶(lactic dehydrogenase,LDH)浓度、1年内有无进展、病理类型组别中的基线SUV_max均值差异有统计学意义;②以1年进展率为截点,ROC曲线上SUV_max最佳临界点为14.4,以14.4为界限值进行分组,发现SUV_max＜14.4组患者中位无进展生存时间(progression-free survival, PFS)、中位总生存期(overall survival, OS)均远远高于SUV_max≥14.4组;③以随访结束后患者疾病进展为截点,SUV_max最佳临界点为16.7,以16.7为界限值进行分组,发现SUV_max＜16.7组患者中位PFS远高于SUV_max≥16.7组(P=0.025)。结论 B细胞型非霍奇金淋巴瘤患者的基线SUV_max与疗效及生存预后有密切关系,具有很大的临床应用价值。

关键词: B细胞型非霍奇金淋巴瘤, 18 氟-氟代脱氧葡萄糖-正电子发射计算机断层显像, 最大标准化摄取值, 无进展生存时间, 总生存期

Abstract: Objective To evaluate the efficacy and prognostic value of maximum standardized uptake (SUV_max) of ¹⁸F-flurodeoxyglucose positron emission tomography/computed tomography(¹⁸F-FDG PET/CT) in B-cell non-Hodgkin's lymphoma (NHL). Methods A total of 47 patients with B-cell non-Hodgkin's lymphoma treated in Beijing Shijitan Hospital, Capital Medical University from August 2016 to September 2019 were retrospectively analyzed. The correlation between baseline SUV_max and clinicopathological factors, laboratory indexes was evaluated. Receiver operating characteristic (ROC) curve analysis was used to determine the optimal point of SUV_max for disease progression, and the prognostic value of SUV_max was analyzed. Results ①There were significant differences between the baseline SUV_max and lactic dehydrogenase(LDH) level, progression status within 1 year, pathological types, respectively; ②Take the 1-year progression rate as the cut-off point, the optimal point of SUV_max was 14.4, the median progression-free survival (PFS) and overall survival (OS) of patients with SUV_max＜14.4 were significantly higher than those with SUV_max≥14.4,P<0.05; ③Take the disease progression as the cut-off point, the optimal pointof SUV_max was 16.7, the median PFS of patients with SUV_max＜16.7 were significantly higher than those with SUV_max≥16.7,P=0.025. Conclusion Baseline SUV_max of patients with B-cell lymphoma is closely related to the curative effect and survival, which has great clinical value.

Key words: B-cell non-Hodgkin's lymphoma, ¹⁸F-flurodeoxyglucose positron emission tomography/computed tomography(¹⁸F-FDG PET/CT), maximum standardized uptake, progression-free survival, overall survival

中图分类号:

R733

郭晓川, 张伟京, 王斌, 王伟霞, 黄乐富, 曹宝平, 仲凯励. 基线¹⁸F-FDG PET／CT最大标准摄取值与B细胞非霍奇金淋巴瘤临床疗效及预后的关系[J]. 首都医科大学学报, 2021, 42(5): 829-835.

Guo Xiaochuan, Zhang Weijing, Wang Bin, Wang Weixia, Huang Lefu, Cao Baoping, Zhong Kaili. The efficacy and prognostic value of maximum standard uptake on baseline ¹⁸ F-FDG PET/CT in B-cell non-Hodgkin's lymphoma[J]. Journal of Capital Medical University, 2021, 42(5): 829-835.

参考文献

[1] 李小秋, 李甘地, 高子芬,等.中国淋巴瘤亚型分布:国内多中心性病例10 002例分析[J].诊断学理论与实践, 2012, 11(2): 111-115.
[2] Ansell S M, Armitage J O. Positron emission tomographic scans iIl lymphoma: convention and controversy[J]. Mayo Clin Proc, 2012, 87(6):571-580.
[3] Deng S M, Zhang W, Zhang B, et al. Correlation between the uptake of ¹⁸F-fluorodeoxyglucose (18F-FDG) and the expression of proliferation-associated antigen Ki-67 in cancer patients: a meta-analysis[J]. PLoS One, 2015,10(6):e0129028
[4] Cheson B D, Fisher R I, Barrington S F, et al. Recommendations for initial evaluation,staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification[J]. J Clin Oncol, 2014,32(27):3059-3068.
[5] Berzacyz D, Haug A, Staber P B, et al. RECIL versus lugano for treatment response assessment in FDG-avid non-hodgkin lymphomas: a head-to-head comparison in 54 patients [J]. Cancer (Basel), 2019,12(1):9.
[6] Li X, Sun X, Li J, et al. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma[J]. Cancer Med, 2019,8(11):5012-5022.
[7] Zhou Y, Zhao Z, Li J, et al. Prognostic values of baseline, interim and end-of therapy 18F-FDG PET/CT in patients with follicular lymphoma[J]. Cancer Manag Res, 2019(11): 6871-6885.
[8] St-pierre F, Broski S M, LaPlant B R, et al. Fluorodeoxyglucose positron emission tomography predicts bone marrow involvement in the staging of follicular lymphoma[J]. Oncologist, 2020, 25(8):689-695.
[9] Xia J,Zhu H Y, Liang J H, et al. The prognostic role of 18F-FDG PET/CT baseline quantitative metabolic parameters in peripheral T-cell lymphoma[J]. Cancer, 2019, 10(23): 5805-5811.
[10]Albano D, Bosio G, Bianchetti N, et al. Prognostic role of baseline 18FFDG PET/CT metabolic parameters in mantle cell lymphoma[J]. Ann Nucl Med, 2019, 33(7):449-458.
[11]Jeon Y W, O J H, Park K S, et al. Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R‐CHOP [J]. Br J Haematol, 2020, 188(6):860-871..
[12]Huang H, Xiao F, Han X, et al. Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma[J].Nucl Med Commun, 2016, 37(7): 689-698.
[13]Ngeow J Y Y, Quek R H H, Ng D C E, et al. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma[J]. Ann Oncol, 2009, 20(9):1543-1547.
[14]王小沛,黄惠颖,应志涛,等.化疗中期及化疗后¹⁸F-FDG PETCT检查对侵袭性T细胞淋巴瘤患者生存期的预测价值[J].中华血液学杂志, 2014,35(4):350-352.
[15]Gallicchio R, Mansueto G, Simeon V, et al. F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma[J]. Eur J Haematol, 2014,92(5):382-389.
[16]Adams H J, de Klerk J M, Fijnheer R, et al. Prognostic superiority of the national comprehensive cancer network international prognostic index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma[J]. Eur J Haematol, 2015, 94(6):532-539.
[17]Papajik T, Myslive6ek M, Sedova Z, et al. Standardized uptake value of ¹⁸F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma[J]. Eur J Haematol,2011, 86(1): 32-37.
[18]Ucar E, Yalcin H, Kavvasoglu G H, et al. Correlations between the maximum standard uptake value of positron emission tomography/computed tomography and laboratory parameters before and after treatment in patients with lymphoma[J]. Chin Med J (Engl), 2018,131(15):1776-1779.
[19]Miyazaki Y, Nawa Y, Miyagawa M, et al. Maximum standard uptake value of 18F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma[J]. Ann Hematol, 2013,92(2):239-244.
[20]王瑞民, 徐白萱, 刘长滨,等. FDG与FLT PET-CT在初诊弥漫大B细胞淋巴瘤预后评估中的作用[J].中华血液学杂志,2018,39(1):56-59.

基线¹⁸F-FDG PET／CT最大标准摄取值与B细胞非霍奇金淋巴瘤临床疗效及预后的关系

The efficacy and prognostic value of maximum standard uptake on baseline ¹⁸ F-FDG PET/CT in B-cell non-Hodgkin's lymphoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王慧娟, 杨光忠, 菅原, 耿传营, 周慧星, 陈文明. VRD与VCD方案诱导治疗后序贯自体造血干细胞移植对新诊断的多发性骨髓瘤患者的疗效分析[J]. 首都医科大学学报, 2021, 42(4): 615-622.
[2]	贾晨光, 周翾, 王彬, 朱光华, 秦茂权. 异基因造血干细胞移植治疗儿童急性髓系白血病的临床观察[J]. 首都医科大学学报, 2019, 40(2): 163-168.
[3]	张利强, 陈振萍, 郑杰, 马洁, 吴润晖. 国产甲磺酸伊马替尼治疗儿童慢性髓系白血病慢性期的早期疗效和安全性分析[J]. 首都医科大学学报, 2019, 40(2): 174-178.
[4]	彭晓娟, 张睿娟, 王梅芳, 张耀方, 覃艳红, 杨林花. 地西他滨序贯或同时联合“3+7”方案在45例初发急性髓系白血病中治疗效果分析[J]. 首都医科大学学报, 2019, 40(2): 300-304.
[5]	马小雯, 董春霞, 陈剑芳, 王梅芳, 张睿娟, 张建华, 杨林花. 外周血单核细胞绝对计数对慢性淋巴细胞白血病预后判断的价值[J]. 首都医科大学学报, 2018, 39(4): 581-585.
[6]	秦娜, 李广波, 郭树霞, 张晓娟. MicroRNA-221（miR-221）抑制p27^Kip1蛋白促进慢性粒细胞白血病的发生[J]. 首都医科大学学报, 2017, 38(4): 580-585.
[7]	段彦龙, 金玲, 杨菁, 黄爽, 张梦, 赖瑞, 周春菊, 张永红. 儿童伯基特白血病26例临床研究[J]. 首都医科大学学报, 2016, 37(2): 141-147.
[8]	吴学宾. 慢性中性粒细胞白血病[J]. 首都医科大学学报, 2014, 35(5): 577-580.
[9]	王敏, 王立茹, 崔建英, 周合冰. 高白细胞急性髓系白血病TGF-β₁的表达及其临床意义[J]. 首都医科大学学报, 2014, 35(5): 555-559.
[10]	孟广强, 王立茹, 陈以娟, 张晶晶, 王敏, 郭慧霞, 武悦. 白细胞分离术在高白细胞急性白血病中的临床应用[J]. 首都医科大学学报, 2014, 35(5): 566-571.
[11]	王晶;赵灵芝;克晓燕. 制备淋巴瘤多基因肿瘤疫苗的方法学探索[J]. 首都医科大学学报, 2008, 29(2): 118-123.
[12]	黄红铭;侯健;周帆;姜华. 硼替佐米对多发性骨髓瘤患者破骨细胞分化和功能的影响[J]. 首都医科大学学报, 2008, 29(2): 124-127.
[13]	王同国;史斌;王昕;王立茹;陈以娟. 细胞因子对K562细胞HSP gp96基因及蛋白表达的影响[J]. 首都医科大学学报, 2008, 29(2): 128-132.
[14]	王小平;郭尔安;齐巍;张伟;张懋植. 免疫适任者原发性中枢神经系统淋巴瘤(附125例病例分析)[J]. 首都医科大学学报, 2008, 29(2): 218-221.
[15]	刘欣;曾少举;王永潮. 分化抑制因子Id4对K562细胞株凋亡的影响[J]. 首都医科大学学报, 2006, 27(5): 607-611.